sapacitabine

Known as: 2'-C-cyano-2'-deoxy-1-arabinofuranosyl-N(4)-palmitoylcytosine, CNDAC cpd, N-(1-(2-Cyano-2-deoxy-beta-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl)-hexadecanamide 
An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2016
024619952016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
PURPOSE The double-strand breaks elicited by sapacitabine, a clinically active nucleoside analogue prodrug, are repaired by RAD51… (More)
Is this relevant?
2012
2012
BACKGROUND Available treatments for acute myeloid leukaemia (AML) have limited durable activity and unsatisfactory safety… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2012
2012
Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2012
Review
2012
INTRODUCTION Sapacitabine is an orally bioavailable nucleoside analog prodrug that is in clinical trials for hematologic… (More)
Is this relevant?
2011
2011
6587 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks… (More)
Is this relevant?
2010
2010
PURPOSE Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • table 5
Is this relevant?
2010
2010
Background:Alternative treatments are needed for elderly patients with acute myeloid leukaemia, as the disease prognosis is poor… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Causing damage to angiogenic vessels is a promising approach for cancer chemotherapy. The present study is a codification of a… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2007
2007
This study assessed the antiproliferative activity of sapacitabine (CYC682, CS-682) in a panel of 10 human cancer cell lines with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
Cyclacel Pharmaceuticals, under license from Sankyo Co, is developing the prodrug sapacitabine for the potential treatment of… (More)
Is this relevant?